MAIA Biotechnology Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

MAIA Biotechnology Stock Summary

MAIA Biotechnology competes with Lineage Cell, Armata Pharmaceuticals, Portage Biotech, Larimar Therapeutics, and Lyra Therapeutics. MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. The company was founded in 2018 and is headquartered in Chicago, Illinois. Maia Biotechnology operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 9 people.

MAIA Biotechnology Key Financial Ratios

MAIA Biotechnology Key Balance Sheet Accounts

MAIA Biotechnology Key Income Statement Accounts

MAIA Biotechnology Key Cash Accounts

MAIA Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining MAIA Biotechnology's current stock value. Our valuation model uses many indicators to compare MAIA Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MAIA Biotechnology competition to find correlations between indicators driving MAIA Biotechnology's intrinsic value. More Info.MAIA Biotechnology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, MAIA Biotechnology's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MAIA Biotechnology's earnings, one of the primary drivers of an investment's value.

MAIA Biotechnology Systematic Risk

Today, most investors in MAIA Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MAIA Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MAIA Biotechnology growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of MAIA Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MAIA Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of MAIA Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing MAIA Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MAIA Biotechnology's daily price indicators and compare them against related drivers.

When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.